Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...(penses: Cost of sales ...),Health

Date:2/27/2009

penses: Cost of sales 267,235 - 267,235 Selling, general and administrative 488,063 (27,973) (1) 460,090 Research and development 110,211 (18,843) (2) 91,368 Impairment of other intangible assets 8,083 (8,083) (3) - Purchased in-process research and development (530) 530 (4) - Operating income 387,474 54,369 441,843 Interest expense 8,354 - 8,354 Interest and other income, net (23,080) (3,320) (5) (26,400) Income before income taxes 402,200 57,689 459,889 Income taxes 140,459 22,265 (6) 162,724 Net income $261,741 $35,424 $297,165 Diluted earnings per share $2.12 $2.40 Diluted weighted average shares 123,720 123,602 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude stock-based compensation ($15,492), separation benefits ($10,459), contract termination costs ($540) and asset impairment charges ($1,482). (2) To exclude stock-based compensation ($1,442), upfront and milestone payments to partners ($8,910), separation benefits ($825), contract termination costs ($4,551) and asset impairment charges ($3,115). (3) To exclude impairment of other intangible assets. (4) To exclude purchased in-process research and development. (5) To exclude changes in fair value of financial instruments, net. (6) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.

    Year Ended December 31
'/>"/>
SOURCE  Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results